Treating Alzheimer's Disease: A Plan for Symptoms, Disease Progression, and Everyday Life

When a parent starts asking the same question repeatedly or a partner becomes lost on a familiar journey, the immediate wish is often for a treatment that will restore life as it was. Alzheimer's disease still has no cure. There are, however, several useful kinds of treatment, and selected people with early disease can now be assessed for medicines intended to slow its progression. A workable plan combines an accurate diagnosis, realistic medication decisions, attention to other health problems, and support that fits the person's daily life. It should also explain how the family will know whether the plan needs to change. NIA treatment overview

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Alzheimer's is one cause of dementia, rather than another name for every memory complaint. Poor sleep, depression, hearing difficulty, medication effects, vascular disease, and other neurological conditions can affect thinking. Several contributors may coexist. The timing matters: a gradual change over years calls for a different assessment from confusion that developed over a few days. Sudden weakness, new speech difficulty, or an abrupt change in alertness needs prompt local medical assessment, even in someone with an established dementia diagnosis.
Amyloid-directed antibodies can cause amyloid-related imaging abnormalities, or ARIA. These include swelling and bleeding-related changes in the brain. Some abnormalities produce no symptoms; others can be serious or fatal. New headache, unusual confusion, visual changes, difficulty walking, seizures, or stroke-like symptoms require timely assessment. Emergency clinicians need to know which antibody the person is receiving because ARIA can resemble an ischemic stroke and can affect decisions about treatment.
There is no routine operation that removes Alzheimer's disease. In China, the National Health Commission prohibited the clinical use of deep cervical lymphatic vessel or node-to-vein anastomosis for Alzheimer's treatment in 2025 because adequate evidence of safety and effectiveness was lacking. A biological theory or a proposal for research does not establish a proven commercial treatment. Similar care is needed with claims about cells, devices, or other interventions advertised as restoring memory. National Health Commission notice

Quick answer

Full guide

Establish what is causing the difficulty

Alzheimer's is one cause of dementia, rather than another name for every memory complaint. Poor sleep, depression, hearing difficulty, medication effects, vascular disease, and other neurological conditions can affect thinking. Several contributors may coexist. The timing matters: a gradual change over years calls for a different assessment from confusion that developed over a few days. Sudden weakness, new speech difficulty, or an abrupt change in alertness needs prompt local medical assessment, even in someone with an established dementia diagnosis.

The person experiencing the symptoms should have an opportunity to describe them. Someone who knows their usual routine can then provide examples the patient may not have noticed. Being unable to manage previously familiar bills or medicines, needing repeated directions for cooking, or losing track of appointments can be more informative than an isolated memory lapse. The clinician brings this history together with an examination, cognitive assessment, and appropriate laboratory or imaging investigations. NIA diagnosis guide

A short test score is not a diagnosis by itself. Education, preferred language, hearing, vision, fatigue, and anxiety can affect performance. This matters particularly for a person attending a clinic in another country. Ask how testing will be conducted in a language the patient understands and whether an appropriately trained interpreter is available. A score obtained under unsuitable conditions should not be treated as proof that the disease has suddenly become more severe. Contemporary diagnostic guidance places the clinical history and functional assessment alongside the tests. DETeCD-ADRD recommendations

Separate the cause of impairment from its clinical stage

Mild cognitive impairment describes measurable cognitive difficulty while much everyday independence remains. Dementia means that cognitive impairment interferes with independent daily functioning. Within dementia, the amount and kind of help needed vary considerably. A person may require supervision for complex financial decisions while still dressing, eating, and enjoying conversation independently. Another may have prominent language or visual processing difficulties rather than a chiefly amnestic presentation.

Biomarker tests address another part of the assessment: whether changes associated with Alzheimer's pathology are present. They do not directly measure the amount of practical help someone needs, and a positive result is not a personal timetable for future disability. Blood tests, cerebrospinal fluid analysis, and amyloid PET have different roles. The 2025 blood biomarker guideline supports appropriately validated tests in defined specialist settings, with different accuracy requirements for triage and confirmation. It also warns that commercial tests vary. A result labelled p-tau cannot be assumed to have the same meaning across every laboratory and method. Blood biomarker clinical practice guideline

For families, the useful questions are therefore specific: what diagnosis best explains the symptoms, how confident is the clinician, what uncertainty remains, and would another test change management? Ordering every available scan can create cost and distress without answering a new question. Conversely, someone being evaluated for an amyloid-directed medicine may need evidence that was unnecessary for an earlier general memory consultation.

Use symptom medicines with observable goals

Donepezil, rivastigmine, and galantamine are cholinesterase inhibitors used for Alzheimer's symptoms. Memantine acts through a different mechanism and is generally considered in more advanced stages. Selection depends on the clinical stage, previous response, tolerability, other medical conditions, and the full medication list. Appetite, weight, gastrointestinal symptoms, pulse, kidney function, and the ability to take medicines reliably may affect the decision. Exact indications and available formulations should be checked in the country providing care.

The goal of a symptom medicine is easier to discuss when it is connected to something observable. A family might monitor whether the person can participate in a meal, follow a familiar dressing routine with prompts, or remain awake enough to enjoy an afternoon activity. This does not turn informal observations into a clinical trial, but it gives the prescriber a more useful account than “good days and bad days.” Record troublesome effects as well as possible benefits.

Continuing decline does not automatically prove that the medicine has done nothing; Alzheimer's may progress despite a partial symptomatic benefit. Equally, a brief improvement in attention is not evidence that the underlying disease has been reversed. Decisions to continue, change, or withdraw treatment require review of benefit, burden, safety, and preferences. NICE specifically advises against stopping a cholinesterase inhibitor solely because Alzheimer's has become more severe. Its prescribing and funding arrangements are British guidance, not a statement of Chinese coverage. NICE dementia recommendations

Consider disease-modifying treatment only in the relevant population

Lecanemab and donanemab are amyloid-directed antibodies. Their clinical evidence concerns early symptomatic Alzheimer's, including mild cognitive impairment due to the disease and mild Alzheimer's dementia, with appropriate evidence of amyloid pathology. They should not be presented as a treatment for every type of forgetfulness, for all dementia stages, or for an otherwise well person who is simply worried about future risk.

An assessment also considers MRI findings, previous bleeding, other illnesses, concomitant medicines, and the ability to complete follow-up. A person may have the relevant diagnosis yet still have risks or practical limitations that make treatment unsuitable. The appointment should allow discussion of declining treatment as well as accepting it. Symptom management and supportive care continue to matter regardless of that choice.

In the CLARITY AD randomized trial, people receiving lecanemab had less average worsening on measures of cognition and function over 18 months than those receiving placebo. The familiar statement about slowing decline describes a difference between groups. It does not mean a corresponding percentage of lost memory returned. Donanemab also reduced average clinical progression in its pivotal trial, but the studies differed in their populations and methods. Their headline percentages cannot establish which medicine is best for an individual. CLARITY AD, TRAILBLAZER-ALZ 2

Make monitoring part of the treatment decision

Amyloid-directed antibodies can cause amyloid-related imaging abnormalities, or ARIA. These include swelling and bleeding-related changes in the brain. Some abnormalities produce no symptoms; others can be serious or fatal. New headache, unusual confusion, visual changes, difficulty walking, seizures, or stroke-like symptoms require timely assessment. Emergency clinicians need to know which antibody the person is receiving because ARIA can resemble an ischemic stroke and can affect decisions about treatment.

Monitoring cannot be reduced to asking whether the patient feels well after an injection. MRI is used before and during treatment, and findings must be reviewed before decisions about further dosing. For example, the July 2026 US lecanemab label specifies baseline MRI and imaging after one, two, three, and six months of treatment, with timing that accommodates intravenous and subcutaneous dosing. The treating team in China should use the current locally applicable instructions rather than copy an old overseas infusion checklist. Current US lecanemab prescribing information

APOE ε4 status is relevant to the discussion of ARIA risk, particularly for people with two copies. Testing also has implications for how a family understands inherited risk, so the meaning should be discussed before testing. It is not a stand-alone decision about whether someone should receive an antibody. Anticoagulant use, previous intracerebral hemorrhage, MRI abnormalities, or inability to undergo the necessary imaging require particular attention. A patient should never independently stop an anticoagulant to try to qualify for Alzheimer's treatment.

Check what is actually available in China

Donanemab has a formal manufacturer announcement of approval in China for early symptomatic Alzheimer's disease. A further important change was announced on September 3, 2026: the subcutaneous lecanemab formulation for initiation of treatment had received Chinese approval. The announcement described a planned launch within Eisai's fiscal year ending March 31, 2027. Approval therefore should not be translated into a promise that a particular hospital can supply the formulation on the date of this article's review, September 9, 2026. Donanemab China announcement, Subcutaneous lecanemab China announcement

The hospital needs to confirm the actual product, local prescribing criteria, pharmacy supply, and monitoring arrangements. Home administration, where available and appropriate, still requires training and access to professional help. It does not remove the need for imaging or make the treatment suitable for unsupervised use.

For an international patient, feasibility extends beyond the first visit. Before travelling, clarify who will prescribe after return home, who will obtain and interpret follow-up MRI, and where urgent problems will be assessed. The financial estimate should include diagnostic confirmation, clinical visits, monitoring, administration where relevant, and the practical cost of a companion. A single injection price is not the cost of a functioning treatment pathway. An approval announcement also does not establish insurance reimbursement, overseas patient eligibility, or immediate appointment availability.

Build support around the person's remaining abilities

Predictable routines, clear prompts, suitable activities, and a less confusing environment can make ordinary tasks more manageable. Addressing hearing, vision, pain, constipation, and sleep difficulties may improve communication or reduce distress. When agitation appears, consider what happened beforehand: a noisy room, an unfamiliar caregiver, hunger, fear, or discomfort may be contributing. Medication can be appropriate in particular circumstances, but it should have a defined target and be reviewed for harms such as sedation or falls.

Support should preserve participation where possible. Someone who struggles to plan an entire morning may still choose between two outfits or help prepare a familiar snack. Tasks involving medicines, money, cooking hazards, or getting lost may need additional supervision. These decisions are best linked to observed ability and risk rather than to a diagnostic label alone. Written instructions and a named contact can help the family carry out a plan consistently. NIA guidance on caring for people with cognitive impairment

Caregiver capacity is also a clinical concern. Repeated night waking, exhaustion, and lack of a replacement caregiver can make an otherwise sensible plan impossible. Discussing these problems is part of treatment planning. The person with Alzheimer's should remain involved in decisions to the extent they can participate, including preferences for daily routines and future support.

Assess claims of rapid reversal against the evidence

There is no routine operation that removes Alzheimer's disease. In China, the National Health Commission prohibited the clinical use of deep cervical lymphatic vessel or node-to-vein anastomosis for Alzheimer's treatment in 2025 because adequate evidence of safety and effectiveness was lacking. A biological theory or a proposal for research does not establish a proven commercial treatment. Similar care is needed with claims about cells, devices, or other interventions advertised as restoring memory. National Health Commission notice

A useful plan identifies the current diagnosis, the most important daily difficulties, the options being considered, and what will be reassessed. Early in the illness, maintaining work or managing familiar activities may be central. Later, comfortable eating, reduced fear, safe mobility, and sustainable caregiving may become more important. Changing these priorities is a normal part of care. Each review should leave the family understanding the purpose of treatment and the next decision, rather than simply adding another medicine to the list.